Investor Update

Basel, 05 October 2012

Anti-Cancer Agent “Avastin®,” Application for Approval of Additional Indication of Ovarian Cancer

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.